Systematic review and meta-analysis on vitamin D receptor polymorphisms and cancer risk

[1]  Jing-quan Li,et al.  Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis , 2013, PloS one.

[2]  J. Marks,et al.  Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women. , 2013, Gynecologic oncology.

[3]  J. Vadgama,et al.  Vitamin D Receptor Gene Polymorphisms and Prognosis of Breast Cancer among African-American and Hispanic Women , 2013, PloS one.

[4]  K. Majidzadeh-A,et al.  BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer , 2013, Medical Oncology.

[5]  P. Jagodziński,et al.  Vitamin D receptor gene BsmI and FokI polymorphisms in relation to ovarian cancer risk in the Polish population. , 2013, Genetic testing and molecular biomarkers.

[6]  A. Sigurdson,et al.  Sunlight, polymorphisms of vitamin D-related genes and risk of breast cancer. , 2013, Anticancer research.

[7]  J. Olson,et al.  An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome , 2012, Cancer Causes & Control.

[8]  Bi-cheng Chen,et al.  Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic meta-analysis. , 2012, World journal of gastroenterology.

[9]  R. Millikan,et al.  Vitamin D receptor polymorphisms in patients with cutaneous melanoma , 2012, International journal of cancer.

[10]  N. Lei,et al.  Meta-analysis of the relation between the VDR gene TaqIpolymorphism and genetic susceptibility to prostate cancer in Asian populations. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[11]  T. Isbir,et al.  Association of vitamin D receptor Taq I polymorphism and susceptibility to oral squamous cell carcinoma. , 2010, In vivo.

[12]  F. Clavel-Chapelon,et al.  Vitamin D receptor and calcium sensing receptor polymorphisms and the risk of colorectal cancer in European populations. , 2009, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[13]  E. Bertone-Johnson.  Vitamin D and breast cancer. , 2009, Annals of epidemiology.

[14]  Sara Gandini,et al.  Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. , 2009, Carcinogenesis.

[15]  J. Stanford,et al.  Vitamin D Pathway Gene Variants and Prostate Cancer Risk , 2009, Cancer Epidemiology Biomarkers & Prevention.

[16]  J. Buring,et al.  Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. , 2009, Cancer research.

[17]  Chunbo Tang,et al.  Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis , 2009, Breast Cancer Research and Treatment.

[18]  Simone Mocellin,et al.  Vitamin D receptor polymorphisms and the risk of cutaneous melanoma , 2008, Cancer.

[19]  R. Shore,et al.  Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. , 2008, Cancer letters.

[20]  J. Chang-Claude,et al.  Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk , 2008, Breast Cancer Research.

[21]  J. Stanford,et al.  Comprehensive Association Analysis of the Vitamin D Pathway Genes, VDR, CYP27B1, and CYP24A1, in Prostate Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[22]  D. Trump,et al.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.

[23]  J. Michael Gaziano,et al.  A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, and Prostate Cancer , 2007, PLoS medicine.

[24]  G. Colditz,et al.  Polymorphisms in the MTHFR and VDR genes and skin cancer risk. , 2006, Carcinogenesis.

[25]  A. Norman,et al.  Minireview: vitamin D receptor: new assignments for an already busy receptor. , 2006, Endocrinology.

[26]  R. Wolff,et al.  Associations between BMI, energy intake, energy expenditure, VDR genotype and colon and rectal cancers (United States) , 2004, Cancer Causes & Control.

[27]  A. Uitterlinden,et al.  Genetics and biology of vitamin D receptor polymorphisms. , 2004, Gene.

[28]  M. Haussler,et al.  Molecular Nature of the Vitamin D Receptor and its Role in Regulation of Gene Expression , 2001, Reviews in Endocrine and Metabolic Disorders.

[29]  Cancer Epidemiol Biomarkers Prev , 2004 .

[30]  J. Stephenson.  Breast Cancer Risk , 2003 .

[31]  S. Miettinen,et al.  Antiproliferative action of vitamin D. , 2002, Vitamins and hormones.

[32]  C. Ulrich,et al.  Vitamin D receptor polymorphism and the risk of colorectal adenomas: evidence of interaction with dietary vitamin D and calcium. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[33]  M. Galligan,et al.  Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene , 2001, Molecular and Cellular Endocrinology.

[34]  H. Pols,et al.  Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1,25‐dihydroxyvitamin D3 , 2000, Clinical endocrinology.

[35]  J. Chudek,et al.  Plasma parathyroid hormone, phosphatemia and vitamin D receptor genotype: are they interrelated? , 2000, Journal of nephrology.

[36]  J. Cauley,et al.  Molecular epidemiology of vitamin D receptor gene variants. , 2000, Epidemiologic reviews.

[37]  C. Glass,et al.  Coactivator and corepressor complexes in nuclear receptor function. , 1999, Current opinion in genetics & development.

[38]  M. Haussler,et al.  The Nuclear Vitamin D Receptor: Biological and Molecular Regulatory Properties Revealed , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  P. Malloy,et al.  Vitamin D receptor gene polymorphisms: analysis of ligand binding and hormone responsiveness in cultured skin fibroblasts. , 1998, Biochemical and biophysical research communications.

[40]  M. Campbell,et al.  Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. , 1997, Journal of molecular endocrinology.

[41]  H. DeLuca,et al.  Effect of Vitamin D Receptor Genotypes on Calcium Absorption, Duodenal Vitamin D Receptor Concentration, and Serum 1,25 Dihydroxyvitamin D Levels in Normal Women , 1997, Calcified Tissue International.

[42]  H. Yamamoto,et al.  Structural organization of the human vitamin D receptor chromosomal gene and its promoter. , 1997, Molecular endocrinology.

[43]  Y. Taketani,et al.  A Vitamin D Receptor Gene Polymorphism in the Translation Initiation Codon: Effect on Protein Activity and Relation to Bone Mineral Density in Japanese Women , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  P. Roberson,et al.  Quantification of Vitamin D Receptor mRNA by Competitive Polymerase Chain Reaction in PBMC: Lack of Correspondence with Common Allelic Variants , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[45]  R. Marcus,et al.  The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal mexican‐American women , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[46]  J. Eisman,et al.  Prediction of bone density from vitamin D receptor alleles , 1994, Nature.

[47]  S. Manolagas,et al.  Vitamin D and the hematolymphopoietic tissue: a 1994 update. , 1994, Seminars in nephrology.

[48]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[49]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.